| 货号 | 13212-1mg |
| 描述 | Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases (HDACs).1 Unlike the HDAC inhibitor suberoylanilide hydroamic acid, which has a fast-on/fast-off HDAC binding rate, pimelic diphenylamide 106 progressively binds HDACs and remains bound after wash-out. As a result, the IC50 of pimelic diphenylamide 106 decreases over time. With prolonged preincubation (1-3 hours), pimelic diphenylamide inhibits the class I HDACs (IC50 = 150, 760, 370, and 5,000 nM for HDAC1, 2, 3, and 8, respectively) but not the class II HDACs (IC50 > 180 μM for HDAC4, 5, and 7).1 Pimelic diphenylamide 106 and related benzamide HDAC inhibitors may have therapeutic value in Friedrich’s ataxia1,2,3 and Huntington’s disease,4 in part due to their low animal toxicity. |
| 别名 | TC-H 106;Histone Deacetylase Inhibitor VII; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Chou, C.J.,Herman, D., and Gottesfeld, J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. The Journal of Biological Chemisty 283(51), 35402-35409 (2008). 2.Rai, M.,Soragni, E.,Jenssen, K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 3(4), (2008). 3.Herman, D.,Jenssen, K.,Burnett, R., et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nature Chemical Biology 2(10), 551-558 (2006). 4.Thomas, E.A.,Coppola, G.,Desplats, P.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington’s disease transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 105(40), 15564-15569 (2008). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 339.4 |
| 分子式 | C20H25N3O2 |
| CAS号 | 937039-45-7 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |